DiamiR Reports Validation of Two Families of Brain-Enriched microRNAs as Highly Promising Blood-Based Biomarkers of Mild Cognitive Impairment

January 2, 2014

MONMOUTH JUNCTION, NJ–(Marketwired – January 02, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the publication entitled “Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study” in Aging. Mild Cognitive Impairment is a […]

Read the full article →

Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics

January 2, 2014

Mirna Broadens Rights to Its Lead Cancer Therapeutic Candidate MRX34 BOSTON, MA and AUSTIN, TX–(Marketwired – Jan 2, 2014) – Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their […]

Read the full article →

Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer

November 7, 2013

Expands the Company’s Patent Portfolio in Oncology Therapeutics PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled “Targeting […]

Read the full article →

microRNA-122: Positive Preclinical Profile of a GalNAc-conjugated anti-miR Supports Clinical Development for the Treatment of HCV

November 4, 2013

Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of […]

Read the full article →

IntegraGen Obtains Exclusive License for Oncology Biomarker hsa-miR-31-3p

October 14, 2013

EVRY, France–(BUSINESS WIRE)– IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today that it has finalized an agreement providing the company with exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression free survival […]

Read the full article →

Microlin Bio Inc. Licenses The Ohio State University’s miRNA Patent Portfolio to Advance Cancer Diagnostics & Therapeutics

September 26, 2013

COLUMBUS, Ohio, and NEW YORK, Sept. 26, 2013 /PRNewswire/ – The Ohio State University today announced the signing of an exclusive world-wide agreement with Microlin Bio Inc., licensing a large portfolio of Ohio State’s groundbreaking cancer discoveries. The portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat […]

Read the full article →

MicroRNA-31 Might Predict Lung-Cancer Spread

September 25, 2013

Determining whether lung cancer has spread is critical for identifying the most effective therapy. This study found that high levels of microRNA-31 indicate that the tumor has spread and signals a poor prognosis. The findings might lead to improved treatment for some people with the most common form of lung cancer. COLUMBUS, Ohio – Determining […]

Read the full article →

starBase v2.0: decoding miRNA-ncRNA, miRNA-ceRNA and protein-RNA interaction maps from large-scale CLIP-Seq data

September 23, 2013

starBase v2.0 update available starBase is a database that can be used for decoding miRNA-mRNA, miRNA-ceRNA, miRNA-lncRNA, miRNA-circRNA, miRNA-pseudogene and protein-RNA interaction networks from CLIP-Seq (HITS-CLIP, PAR-CLIP, iCLIP, CLASH) data. starBase v2.0 now also provides visualization, analysis, discovery and downloading of above-mentioned large-scale functional genomics data. Currently, starBase v.20 includes (1)108 CLIP-Seq datasets, (2)~500,000 miRNA-mRNA […]

Read the full article →

Exosome Blood-Based Biomarker Discovery: Eli Lilly Enters Collaboration Agreement with Exosome Diagnostics

September 19, 2013

NEW YORK, Sept. 19, 2013 /PRNewswire/ – Exosome Diagnostics today announced it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit.  Under the agreement, Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and […]

Read the full article →

EpimiRNA Consortium Receives €11.5 Million Funding by EU to Uncover the Effects of microRNA in Epilepsy

September 18, 2013

September 18, 2013 / B3C newswire / - Major new funding for research into epilepsy is announced today. The EpimiRNA Consortium, involving 16 partners from 8 European countries, the USA and Brazil has received €11.5 million funding from the European Union’s Framework Programme 7 to investigate molecular mechanisms, diagnostics and treatments for epilepsy. Over 50 million people […]

Read the full article →